Common stock offering initiated in 2012
Company: Riot
The claim, verbatim
The company raised funds through a common stock offering beginning in 2012 to support remaining development and clinical trial work needed to seek FDA clearance for AppyScore™
Source (primary)
Riot DEF 14A filed 2012-10-15 (SEC EDGAR, sec_filing)
View cached copy (2026-09-27)Live source ↗
Quote: “Since the beginning of 2012, the Company has raised funds through a common stock offering to be used principally to perform the remaining development and clinical trial work needed to seek FDA clearance for its blood-based diagnostic test”
How we checked this
Checked on September 30, 2026. The cited source supports every part of this claim.
The filing states that since the beginning of 2012 the company raised funds through a common stock offering, mainly for the development and clinical work needed to seek FDA clearance for AppyScore.
Confirmed in the source:
- Since the beginning of 2012, the company raised funds through a common stock offering
- The funds were to be used principally for the remaining development and clinical trial work needed to seek FDA clearance for AppyScore
What we did: Read our cached copy of SEC EDGAR (https://www.sec.gov/Archives/edgar/data/1167419/000107997312000796/appy_def14a.htm) in full (92,836 characters, retrieved September 27, 2026) and checked each assertion in the claim against it.
Additional evidence
confirms Riot DEF 14A filed 2012-10-15
Quote: “Since the beginning of 2012, the Company has raised funds through a common stock offering to be used principally to perform the remaining development and clinical trial work needed to seek FDA clearance for its blood-based diagnostic test”